Table 3.
Association between OPG polymorphisms and the risk for DR.
| Polymorphism | Model | Number of cases/controls | OR* (95% CI) | P value |
|---|---|---|---|---|
| rs2073618 (c.9C>G) |
Codominant: | |||
| CC versus GG (reference) | 70/66 versus 78/135 | 2.19 (1.18–4.09) | 0.01 | |
| CG versus GG (reference) | 132/164 versus 78/135 | 1.51 (0.93–2.47) | 0.098 | |
| Dominant: | ||||
| CC + CG versus GG (reference) | 202/230 versus 78/135 | 1.72 (1.08–2.70) | 0.022 | |
| Recessive: | ||||
| CC versus CG + GG (reference) | 70/66 versus 210/299 | 1.75 (1.0–3.05) | 0.05 | |
|
| ||||
| rs3134069 (g.119964988A>C) |
Dominant: | |||
| CC + AC versus AA (reference) | 54/37 versus 226/328 | 1.25 (0.67–2.33) | 0.491 | |
| Recessive: | ||||
| CC versus AC + AA (reference) | 6/1 versus 274/364 | 4.8 (0.45–50.8) | 0.19 | |
*Adjusted for duration of diabetes, insulin therapy, BMI, HbA1c, total LDL, HDL, and cholesterol levels.
Bold indicates statistically significant results.